暂无公司简介
$39.06-4.42%
报价 2026-11-16
市值
$1.83B
EV
$12.3M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -28.9%
$24.98$54.94
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| COAGHemab Therapeutics Holdings, Inc. Common Stock | $1.83B | -4.4% | – | 0% | – | – | – | |
| TRVITrevi Therapeutics, Inc. | $1.89B | -2.6% | – | 0% | – | – | – | |
| ZBIOZenas BioPharma, Inc. | $1.89B | -0.3% | +13.3% | 0% | – | – | – | |
| FTREFortrea Holdings Inc. | $1.87B | -2.0% | -1.9% | 17.1% | – | 34.8x | 12.5x | |
| MAZEMaze Therapeutics, Inc. | $1.85B | -1.3% | +545.2% | 95.3% | – | – | – | |
| ETONEton Pharmaceuticals, Inc. | $1.84B | -0.1% | +126.9% | 69.2% | 36.5x | 40.7x | 48.1x | |
| ZYMEZymeworks Inc. | $1.84B | +0.8% | – | 98.4% | – | – | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $1.81B | -8.8% | -35.0% | -49.8% | – | – | – | |
| AGIOAgios Pharmaceuticals, Inc. | $1.8B | -4.6% | +297.6% | 87.9% | – | – | – | |
| 同行中位数 | – | – | +70.1% | 43.1% | 36.5x | 37.7x | 30.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。
研究材料
Filing 摘要
暂无 filing 摘要。
电话会纪要摘要
暂无纪要摘要。